Cover Image



出版商 Amadee & Company, Inc. 商品編碼 301230
出版日期 內容資訊 英文 373 pages
Back to Top
出版日期: 2014年05月07日 內容資訊: 英文 373 pages






  • 抗生素
  • 對抗生素的抗性
  • 嚴重的事態
  • 抗菌劑所確立的現代醫療
  • 抗生素抗藥性的歷史
  • 問題點
  • 過度使用抗生素的錯誤想法
  • 減少抗生素的開發
  • 成本增加與投資報酬率的減少
  • FDA指導的不足
  • 開發新抗生素的企業
  • 政府的配合 其他


  • 整體市場
  • 各類型市場
  • 各地區市場
  • 各用途市場
  • 市場產品化
  • 市場機會
  • 革蘭氏陰性市場
  • 難治型腸梭菌造成的腹瀉(CDAD)
  • CDAD治療的市場環境
  • Fecal Matter Transplants (FMT)
  • 革蘭氏陽性市場


  • 歷史概要
  • 單一成分藥物
  • 大型製藥公司20年前失去了對植物的關注
  • 新策略的必要性
  • 對植物的案例
  • 新技術的需求
  • FDA和植物性醫藥品
  • 第一個口服植物性醫藥品的新藥申請
  • 美國植物性醫藥品的未來
  • 國際植物性醫藥品 其他


  • 市場規模預測與課題
  • 全球藥用植物生產
  • 全球藥用植物出口
  • 全球藥用植物進口
  • 各類型生產趨勢
  • 競爭環境




An Antibiotic is an agent that either kills or inhibits the growth of a microorganism. The world is now facing a grave situation: it is losing the battle against infectious diseases; bacteria are fighting back and are becoming resistant to modern medicine; in short, pharmaceutical drugs don't work. If resistance is allowed to increase, in a few decades people may start dying from the most commonplace of ailments that today can be treated easily. In fact, the ability of organisms to develop resistance to the effects of antimicrobial therapies developed to kill them is potentially the greatest challenge to healthcare in the 21st century.

Antimicrobial resistance (AMR) is a form of drug resistance whereby some sub-populations of a microorganism, usually a bacterial species, are able to survive after exposure to one or more antibiotics. Pathogens resistant to multiple antibiotics are considered multidrug resistant (MDR) or, more colloquially, superbugs.

The US and world are in the beginning of an emerging crisis of Antibiotic resistance for microbial pathogens. Epidemic antibiotic resistance has been described in numerous pathogens in varying contexts, including, but not limited to: MRSA (methicillin-resistant Staphylococcus aureus), common respiratory pathogens, including Streptococcus pneumoniae and Mycobacterium tuberculosis, and epidemic increases in multidrug-resistant and, increasingly, truly pan-resistant, gram-negative bacilli.

Why is the level of concern increasing now? It is because the increase in organisms resistant to multiple therapies is now coinciding with the reduction in new therapies coming to market to replace ineffective ones.

Herbal medicine, including medicinal plants, was the only way people could treat infectious diseases until the early 20th century. Since then, pharmaceutical drugs have become the main method for treating bacterial infections. However, the pharmaceutical drug pipeline is almost dry. At the same time, growing consumer awareness of the benefits of herbal medicine, along with a backlash against the exorbitant prices and dangerous side effects of pharmaceutical drugs, have led to a renaissance in the use of medicinal plants. Consumers are starting to focus on keeping healthy rather than dealing with acute situations that require the use of expensive pharmaceutical drugs. Medicinal plants fit perfectly into this new paradigm. And for this reason, their use is forecast to grow dramatically.

This report looks at the use of medicinal plants, rather than Antibiotics, to both treat and prevent bacterial infections. Specifically, it provides:

  • A detailed look at Antibiotics and Antimicrobial Resistant drugs.
  • Analysis of the Antibiotics market.
  • In-depth examination of Antibacterial Medicinal Plants.
  • Analysis of the Medicinal Plants market.

Additionally, profiles of 127 private and public companies involved in the Antibiotics and Medicinal Plants industries as producers, distributors, and retailers are given. The report also includes 32 tables and 32 figures.

Table of Contents


  • Background, Spread of MRSA to Households, New Delhi Metallo, Consumers Moving Toward Herbal Medicine, Mainstream Medical Establishments Changing Their Thinking, Consumer Focus Now on Maintaining Health, Outlook for Medicinal Plants Vs. Antibiotic Drugs
  • Report Objectives
  • Methodology and Sources
  • Statistical Notes



  • Antibiotics
  • Antibiotic Resistance
  • Epidemic of Antibiotic-Resistant Infections
  • Grave Situation
  • Modern Healthcare Built on Antimicrobials
  • History of Antimicrobial Resistance
  • Putting the Problem in Context
  • Fallacy of Antibiotic Overuse
  • Decreasing Antibiotic Development
  • Increasing Costs, Decreasing ROI
  • Lack of FDA Guidance
  • Companies Developing New Antibiotic Drugs
  • Government Efforts
  • Multi-Drug Resistance Growing
  • Current Situation
  • Number of AMR Cases Each Year by Type
  • More Needs to Be Done
  • Incentive Problems
  • Economic Costs
  • Cost of MRSA
  • Paradox of Low Impact
  • Limits of Costs of Resistance Assessments
  • Outlook
  • Reducing Uncertainty and Increasing Knowledge
  • Developing Better Incentives
  • International Activity


  • Total Market
  • Market by Type
  • Market by Region
  • Market by Application
  • Market Commoditization
  • Competitive Environment
  • Market Opportunities
  • Gram-negative Market
  • Clostridium difficile-Associated Diarrhea (CDAD)
  • Market Landscape for CDAD Treatments
  • Fecal Matter Transplants (FMTs)
  • Gram-positive Market


  • Historical Context
  • Single-Ingredient Drugs
  • Big Pharma Lost Interest in Plants 20 Years Ago
  • Need for New Strategies
  • Case Against Plants
  • Need for New Technologies
  • FDA and Botanical Drugs
  • First Botanical Drug NDA
  • First Oral Botanical Drug NDA
  • Future of Botanical Drug Products in the US
  • International Botanical Drugs
  • Why Biological Drugs Are Needed
  • Future of Botanical Drugs in the US
  • Scarcity of Disease in Wild Plants
  • Why New Antimicrobial Substances from Plants
  • Plants as a Source of Antimicrobials
  • Plants Synthesize Target-Specific Antibacterials
  • Synergy and Multidrug Resistance Pump Inhibitors
  • Plant Antibacterials Function in Synergy
  • Targeting Bacterial Virulence
  • Future Directions
  • Plant Antibacterials
  • MDR Inhibitors
  • Block Pathogen Virulence
  • Antimicrobial Resistance and Phytochemicals
  • New Therapy Against Resistance
  • Phytotherapy
  • Phytochemicals and Their Classes
  • Secondary Metabolites
  • Phenolics and Polyphenols
  • Mode of Action of Phytochemicals
  • Biofilms and Phytochemicals
  • Quorum-Sensing
  • Phytochemical Products as Antimicrobials and in Biofilm Control
  • Anti-staphylococcal Plant Natural Products
  • Resistance Modifying Agents
  • Methicillin-resistance Reversing Agents
  • Modulators of Multidrug Resistance
  • Antibacterial Natural Products
  • Topical Materials
  • Biological Warfare
  • List of Antimicrobial Plants


  • Market Size Estimation Issues
  • Global Medicinal Plant Production
  • Global Medicinal Plant Exports
  • Global Medicinal Plant Imports
  • Global Medicinal Plant Production by Type
  • Competitive Environment


  • A.A. Sayia & Company, Inc.
  • A. Baur & Co (Pvt.) Ltd.
  • Adam Group
  • Adams Extract & Spice, LLC,
  • Afriplex
  • Akbar Brothers Ltd.
  • Alchem International
  • Alvita Tea
  • Ambo Exports
  • A. M. Todd Botanical Therapeutics, LLC
  • Asian Tea & Exports Ltd.
  • Balaji Agro International
  • Bart Ingredients Company Ltd
  • Bigelow Tea Company
  • Bio Foods Pvt Ltd
  • Brassica Teas
  • Cape Natural Tea Products
  • Ceylon Black Tea Company
  • Ceylon Spice Company
  • C.F. Sauer Company
  • Chamong Tee Exports Pvt. Ltd.
  • Choice Organic Teas
  • Coetzee & Coetzee (Pty) Ltd.
  • Christopher Ranch
  • Cubist Pharmaceuticals, Inc.
  • EOAS International
  • Establecimiento Las Marías
  • Everest Spices
  • Everson Spice Company
  • First Spice Mixing Company
  • Forest Laboratories, Inc.
  • Frontier Natural Products Co-op Inc.
  • Future Generation Co. Ltd
  • Gautam Export Corporation
  • Goya Foods, Inc
  • Hain Celestial Group Inc.
  • Hangzhou Choisun Tea Sci-Tech Co., Ltd.
  • Harney & Sons Tea
  • HDDES Group
  • Herbal Teas International
  • Hong Son Cassia & Star Aniseed Processing Co., Ltd.
  • Hunan Huacheng Biotech Inc.
  • Hunan Kinglong Bio-resource Inc.
  • Huong Que Company
  • Indena
  • Indus Organics
  • Industrial Comercial Holguin E Hijos S.A
  • Integrity Nutraceuticals International Founded
  • Intercom Limited
  • Ishana Spice Exports
  • Jabs International
  • James Finley
  • Jinxiang Luteng Trading Company
  • J. Thomas & Co. Pvt. Ltd
  • Kancor Ingredients Ltd
  • K. Patel Phyto Extractions Pvt. Ltd
  • Kraus
  • La Flor Spices
  • Laila Impex
  • La India Packing Company
  • Laxmi Enterprises
  • L B Spices Trading (Private) Limited
  • LEROS Herbal Teas
  • Lily of the Desert Organic Aloeceuticals
  • Linnea
  • Lipton
  • McCormick & Company, Incorporated
  • Mcleod Russel India Ltd.
  • Mahashian Di Hatti Limited
  • Monteray Bay Spice Company
  • Mountain Rose Herbs
  • Nagata Chaen
  • NHC Foods Ltd.
  • Numi Organic Tea
  • Nutraceuticals International LLC
  • Olam International Limited
  • Olbas
  • Organic India
  • Orient Vietnam Company Limited
  • Out of Africa Trading
  • P.C. Kannan & Co.
  • Peruvian Nature
  • PT Cassia Co-Op
  • PT Dwiwarna Inti Sejahtera
  • Pu-erh Tea Company
  • Quechua Foods S.A.C.
  • Qingdao Xintianfeng Foods Co., Ltd
  • Rathna Producers Cinnamon Exports (Pvt) Ltd.
  • Reindeer Biotech Co., Ltd
  • Republic of Tea
  • Revolution Tea Company
  • Rishi Tea
  • Rooibos Limited
  • Saboor Chatoor (Private) Limited
  • SAMI LABS Limited
  • SDS Spices (PVT) Ltd.
  • Shandong Longtai Fruits and Vegetables Co., Ltd.
  • SNA Tea Company
  • Spice House USA
  • Starwest Botanical
  • Stash Specialty Tea Company
  • Swani Spice Mills Pvt. Ltd.
  • Taifeng Foods Co. Ltd.
  • Taiyo Kagaku Co., Ltd
  • Tata Global Beverages
  • Tazo Tea Company
  • Teavana Holdings, Inc.
  • TEEKANNE GmbH & Co. KG
  • Tetley
  • The Empire Associates
  • The Garlic Company
  • The Medicines Company
  • Time Out Products Inc
  • Topix Pharmaceuticals
  • Traditional Medicinals, Inc.
  • Tripper
  • Twinings Tea
  • United Natural Foods, Inc.
  • Vanns Spices
  • Van Rees
  • Vessey
  • Viet Spice
  • Whole Foods Market, Inc.
  • Xuzhou Hongchang Garlic Co., Ltd.
  • Yerbalatina Phytoactives
  • Yogi Botanicals
  • Yogi Tea
  • YY Tea


  • 1.) Global Production of Antibiotics Vs. Medicinal Plants (USD Million): 2014-2019
  • 2.) Microbes Vs. Humans Metrics
  • 3.) Increased Resource Use and Cost Associated with Infection Resistant Rather than Susceptible Microorganisms Since 2000
  • 4.) Annual Cost-of-Illness for Selected Conditions
  • 5.) Global Antibiotics Market (USD Billion): 2014-2019
  • 6.) Global Antibiotics Market by Type (USD Billion): 2014-2019
  • 7.) Global Antibiotics Market by Region (USD Billion): 2014-2019
  • 8.) 83 Global Manufacturers of Antibiotics and Their Websites
  • 9.) Antibiotic Manufacturers Market Shares (USD Million, %): 2014
  • 10.) Leading Antibiotic Manufacturers by Brand and Type
  • 11.) Higher Mortality Rates in Patients with Resistant Bacteria Compared to Susceptible Strains by Type
  • 12.) Gram-negative Competitive Landscape: Marketed Products by Major Manufacturers-2014
  • 13.) Gram-negative Competitive Landscape-Therapies in Development by Major Manufacturers: 2014
  • 14.) Clostridium difficile-associated diarrhea (CDAD) Competitive Landscape: Marketed Products
  • 15.) Clostridium difficile-associated diarrhea (CDAD) Competitive Landscape: Agents in Development
  • 16.) Gram-positive Market Dynamics
  • 17.) Gram-positive with MRSA Coverage Product and Therapies in Development
  • 18.) Categories of Botanical Therapeutics
  • 19.) Antibacterial to MRSA Plants by Class and Type
  • 20.) Antibacterial Medicinal Plants and Their Species
  • 21.) Global Medicinal Plant Production (USD Million): 2014-2019
  • 22.) Global Medicinal Plant Exports by Country (USD Thousand): 2009-2013
  • 23.) Global Medicinal Plant Imports by Country (USD Thousand): 2009-2013
  • 24.) Global Medicinal Plant Production by Selected Types (USD Million): 2014-2019
  • 25.) 554 Exporters of Turmeri: including company name, products traded, country, website
  • 27.) 130 Importers of Turmeric: including company name, products traded, country, website


  • 1.) Antimicrobial Drug Discovery Timeline
  • 2.) Sigmoidal Development of AMR
  • 3.) MRSA and Gram Negative Markets (Million Days of Therapy): 2013
  • 4.) US and 5 EU Countries Days of Therapy Defined by Select IV Antibiotics: Market Share by Product Type
  • 5.) Key Infections Caused by Gram-negative Pathogens: Market Share by Type
  • 6.) Distribution of Gram-negative Pathogens Causing Healthcare-associated Infections by Type in the United States: 2009-2010
  • 7.) Pathogens Causing Infection in the Intensive Care Unit
  • (% Positive Isolates
  • 8.) Prevalence of Gram-negative Resistance in Urinary Tract Infections (UTIs) in US Hospitals: 2009-2009
  • 9.) Carbapenem Resistance in Gram-negative Pathogens Causing Healthcare-associated Infections in the United States: 2009-2010
  • 10.) Proportion of Escherichia coli Resistant to Fluoroquinolones by Country (%): 2011
  • 11.) Clostridium difficile Overview
  • 12.) Hospital Days of Therapy: US Market Share by Drug (%)
  • 13.) Aggregate Costs for All CDAD-related US Hospital Stays
  • 14.) CDAD Recurrence Rates And Physician Concerns
  • 15.) Structures of Plant Antimicrobials and MDR Inhibitors
  • 16.) Berberis fremontii, Which Produces berberine and 5'-methoxyhydnocarpin
  • 17.) Traditional Targets of Antimicrobial Compounds
  • 18.) Model of Biofilm Development
Back to Top